Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date |
Reported DateTime |
Company | Symbol | Insider Relationship |
Shares Traded |
Average Price |
Total Amount |
Shares Owned |
Filing |
| 2021-09-23 Sale |
2021-09-27 5:51 pm |
iTeos Therapeutics Inc. | ITOS | GADICKE ANSBERT UBS Oncology Impact Fund L.P. BioImpact Capital LLC Oncology Impact Fund (Cayman) Management L.P. 10% Owner |
89,476 | $27.76 | $2,484,094 | 5,429,957 (Indirect) |
View |
| 2021-09-21 Sale |
2021-09-23 4:19 pm |
iTeos Therapeutics Inc. | ITOS | MPM BIOVENTURES 2018 L.P. MPM BioVentures 2018 LLC MPM BioVentures 2018 GP LLC 10% Owner |
33,929 | $27.5 | $933,030 | 3,363,393 (Indirect) |
View |
| 2021-09-21 Sale |
2021-09-23 4:19 pm |
iTeos Therapeutics Inc. | ITOS | MPM BioVentures 2014 L.P. EVNIN LUKE Foley Todd MPM BioVentures 2014 (B) L.P. MPM Asset Management Investors BV2014 LLC MPM BioVentures 2014 LLC MPM BioVentures 2014 GP LLC MPM BIOVENTURES 2018 (B) L.P. MPM ASSET MANAGEMENT INVESTORS BV2018 LLC 10% Owner |
33,929 | $27.5 | $933,030 | 3,363,393 (Indirect) |
View |
| 2021-09-21 Sale |
2021-09-23 4:18 pm |
iTeos Therapeutics Inc. | ITOS | GADICKE ANSBERT UBS Oncology Impact Fund L.P. BioImpact Capital LLC Oncology Impact Fund (Cayman) Management L.P. 10% Owner |
56,779 | $27.5 | $1,561,394 | 5,519,433 (Indirect) |
View |
| 2021-09-16 Sale |
2021-09-20 6:38 pm |
iTeos Therapeutics Inc. | ITOS | MPM BioVentures 2014 L.P. EVNIN LUKE Foley Todd MPM BioVentures 2014 (B) L.P. MPM Asset Management Investors BV2014 LLC MPM BioVentures 2014 LLC MPM BioVentures 2014 GP LLC MPM BIOVENTURES 2018 (B) L.P. MPM ASSET MANAGEMENT INVESTORS BV2018 LLC 10% Owner |
91,254 | $28.38 | $2,590,097 | 3,397,322 (Indirect) |
View |
| 2021-09-16 Sale |
2021-09-20 6:37 pm |
iTeos Therapeutics Inc. | ITOS | MPM BIOVENTURES 2018 L.P. MPM BioVentures 2018 LLC MPM BioVentures 2018 GP LLC 10% Owner |
91,254 | $28.38 | $2,590,097 | 3,397,322 (Indirect) |
View |
| 2021-09-16 Sale |
2021-09-20 6:30 pm |
iTeos Therapeutics Inc. | ITOS | GADICKE ANSBERT UBS Oncology Impact Fund L.P. BioImpact Capital LLC Oncology Impact Fund (Cayman) Management L.P. 10% Owner |
152,711 | $28.38 | $4,334,452 | 5,576,212 (Indirect) |
View |
| 2021-09-14 Sale |
2021-09-16 4:48 pm |
iTeos Therapeutics Inc. | ITOS | MPM BioVentures 2014 L.P. EVNIN LUKE Foley Todd MPM BioVentures 2014 (B) L.P. MPM Asset Management Investors BV2014 LLC MPM BioVentures 2014 LLC MPM BioVentures 2014 GP LLC MPM BIOVENTURES 2018 (B) L.P. MPM ASSET MANAGEMENT INVESTORS BV2018 LLC 10% Owner |
45,665 | $27.7 | $1,264,910 | 3,488,576 (Indirect) |
View |
| 2021-09-14 Sale |
2021-09-16 4:46 pm |
iTeos Therapeutics Inc. | ITOS | MPM BIOVENTURES 2018 L.P. MPM BioVentures 2018 LLC MPM BioVentures 2018 GP LLC 10% Owner |
45,665 | $27.7 | $1,264,910 | 3,488,576 (Indirect) |
View |
| 2021-09-14 Sale |
2021-09-16 4:46 pm |
iTeos Therapeutics Inc. | ITOS | GADICKE ANSBERT UBS Oncology Impact Fund L.P. BioImpact Capital LLC Oncology Impact Fund (Cayman) Management L.P. 10% Owner |
76,417 | $27.7 | $2,116,733 | 5,728,923 (Indirect) |
View |
| 2021-09-09 Sale |
2021-09-13 7:02 pm |
iTeos Therapeutics Inc. | ITOS | GADICKE ANSBERT UBS Oncology Impact Fund L.P. BioImpact Capital LLC Oncology Impact Fund (Cayman) Management L.P. 10% Owner |
96,456 | $28.32 | $2,731,460 | 5,805,340 (Indirect) |
View |
| 2021-09-09 Sale |
2021-09-13 7:01 pm |
iTeos Therapeutics Inc. | ITOS | MPM BioVentures 2014 L.P. EVNIN LUKE Foley Todd MPM BioVentures 2014 (B) L.P. MPM Asset Management Investors BV2014 LLC MPM BioVentures 2014 LLC MPM BioVentures 2014 GP LLC MPM BIOVENTURES 2018 (B) L.P. MPM ASSET MANAGEMENT INVESTORS BV2018 LLC 10% Owner |
57,640 | $28.32 | $1,632,261 | 3,534,241 (Indirect) |
View |
| 2021-09-09 Sale |
2021-09-13 6:59 pm |
iTeos Therapeutics Inc. | ITOS | MPM BIOVENTURES 2018 L.P. MPM BioVentures 2018 LLC MPM BioVentures 2018 GP LLC 10% Owner |
57,640 | $28.32 | $1,632,261 | 3,534,241 (Indirect) |
View |
| 2021-09-07 Sale |
2021-09-08 7:19 pm |
iTeos Therapeutics Inc. | ITOS | GADICKE ANSBERT UBS Oncology Impact Fund L.P. BioImpact Capital LLC Oncology Impact Fund (Cayman) Management L.P. 10% Owner |
71,232 | $29.03 | $2,067,786 | 5,933,136 (Indirect) |
View |
| 2021-09-07 Sale |
2021-09-08 7:13 pm |
iTeos Therapeutics Inc. | ITOS | MPM BioVentures 2014 L.P. EVNIN LUKE Foley Todd MPM BioVentures 2014 (B) L.P. MPM Asset Management Investors BV2014 LLC MPM BioVentures 2014 LLC MPM BioVentures 2014 GP LLC MPM BIOVENTURES 2018 (B) L.P. MPM ASSET MANAGEMENT INVESTORS BV2018 LLC 10% Owner |
42,566 | $29.03 | $1,235,644 | 3,623,221 (Indirect) |
View |
| 2021-09-07 Sale |
2021-09-08 7:12 pm |
iTeos Therapeutics Inc. | ITOS | MPM BIOVENTURES 2018 L.P. MPM BioVentures 2018 LLC MPM BioVentures 2018 GP LLC 10% Owner |
42,566 | $29.03 | $1,235,644 | 3,623,221 (Indirect) |
View |
| 2021-09-01 Sale |
2021-09-03 8:01 pm |
iTeos Therapeutics Inc. | ITOS | Detheux Michel Chief Executive Officer |
20,252 | $28.66 | $580,518 | 105,437 (Direct) |
View |
| 2021-08-27 Sale |
2021-08-31 8:00 pm |
iTeos Therapeutics Inc. | ITOS | Detheux Michel Chief Executive Officer |
14,663 | $28.13 | $412,481 | 125,689 (Direct) |
View |
| 2021-08-23 Sale |
2021-08-25 8:04 pm |
iTeos Therapeutics Inc. | ITOS | Detheux Michel Chief Executive Officer |
8,585 | $28.06 | $240,890 | 140,352 (Direct) |
View |
| 2021-06-14 Sale |
2021-06-16 6:48 pm |
iTeos Therapeutics Inc. | ITOS | Detheux Michel Chief Executive Officer |
29,000 | $28.5 | $826,534 | 148,937 (Direct) |
View |
| 2021-06-16 Purchase |
2021-06-16 6:46 pm |
iTeos Therapeutics Inc. | ITOS | Gall Matthew Chief Financial Officer |
5,000 | $26.09 | $130,447 | 5,000 (Direct) |
View |
| 2021-06-08 Sale |
2021-06-10 5:35 pm |
iTeos Therapeutics Inc. | ITOS | McGrath Yvonne VP, Research and Development |
7,927 | $20 | $158,540 | 95,123 (Direct) |
View |
| 2021-05-24 Sale(A) |
2021-06-03 4:19 pm |
iTeos Therapeutics Inc. | ITOS | McGrath Yvonne VP, Research and Development |
7,927 | $21.92 | $173,796 | 110,977 (Direct) |
View |
| 2021-06-01 Sale |
2021-06-03 4:17 pm |
iTeos Therapeutics Inc. | ITOS | McGrath Yvonne VP, Research and Development |
7,927 | $20.17 | $159,903 | 206,423 (Direct) |
View |
| 2021-05-24 Sale |
2021-05-26 4:09 pm |
iTeos Therapeutics Inc. | ITOS | McGrath Yvonne VP, Research and Development |
7,927 | $21.92 | $173,796 | 110,977 (Direct) |
View |
| 2021-05-17 Sale |
2021-05-19 4:14 pm |
iTeos Therapeutics Inc. | ITOS | McGrath Yvonne VP, Research and Development |
7,926 | $24.69 | $195,719 | 118,904 (Direct) |
View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date |
Reported DateTime |
Exercisable Expiration |
Company | Symnbol | Insider Relationship |
Shares Traded |
Conversion Price |
Shares Owned |
Filing |
| 2021-09-07 Other |
2021-09-08 7:19 pm |
N/A N/A |
iTeos Therapeutics Inc. | ITOS | GADICKE ANSBERT UBS Oncology Impact Fund L.P. BioImpact Capital LLC Oncology Impact Fund (Cayman) Management L.P. 10% Owner |
31,340 | $0 | 5,933,136 (Indirect) |
View |
| 2021-09-07 Other |
2021-09-08 7:13 pm |
N/A N/A |
iTeos Therapeutics Inc. | ITOS | MPM BioVentures 2014 L.P. EVNIN LUKE Foley Todd MPM BioVentures 2014 (B) L.P. MPM Asset Management Investors BV2014 LLC MPM BioVentures 2014 LLC MPM BioVentures 2014 GP LLC MPM BIOVENTURES 2018 (B) L.P. MPM ASSET MANAGEMENT INVESTORS BV2018 LLC 10% Owner |
31,340 | $0 | 3,623,221 (Indirect) |
View |
| 2021-09-07 Other |
2021-09-08 7:12 pm |
N/A N/A |
iTeos Therapeutics Inc. | ITOS | MPM BIOVENTURES 2018 L.P. MPM BioVentures 2018 LLC MPM BioVentures 2018 GP LLC 10% Owner |
31,340 | $0 | 3,623,221 (Indirect) |
View |
| 2021-07-30 Exercise |
2021-08-05 7:55 pm |
N/A 2029-12-04 |
iTeos Therapeutics Inc. | ITOS | Call Matthew Chief Operating Officer |
53,672 | $0 | 201,762 (Direct) |
View |
| 2021-07-30 Exercise |
2021-08-05 7:55 pm |
N/A N/A |
iTeos Therapeutics Inc. | ITOS | Call Matthew Chief Operating Officer |
53,672 | $2.95 | 201,762 (Direct) |
View |
| 2021-06-24 Option Award |
2021-06-25 8:00 pm |
N/A 2031-06-24 |
iTeos Therapeutics Inc. | ITOS | Lager Joanne Jenkins Chief Medical Officer |
24,000 | $0 | 24,000 (Direct) |
View |
| 2021-06-24 Option Award |
2021-06-25 8:00 pm |
N/A 2031-06-24 |
iTeos Therapeutics Inc. | ITOS | Gall Matthew Chief Financial Officer |
24,000 | $0 | 24,000 (Direct) |
View |
| 2021-06-24 Option Award |
2021-06-25 8:00 pm |
N/A 2031-06-24 |
iTeos Therapeutics Inc. | ITOS | Call Matthew Chief Operating Officer |
72,000 | $0 | 72,000 (Direct) |
View |
| 2021-06-17 Option Award |
2021-06-21 8:24 pm |
N/A 2031-06-17 |
iTeos Therapeutics Inc. | ITOS | Biniszkiewicz Detlev Director |
16,608 | $0 | 16,608 (Direct) |
View |
| 2021-06-17 Option Award |
2021-06-21 8:24 pm |
N/A 2031-06-17 |
iTeos Therapeutics Inc. | ITOS | Iannone Robert Director |
4,560 | $0 | 4,560 (Direct) |
View |
| 2021-06-17 Option Award |
2021-06-21 8:23 pm |
N/A 2031-06-17 |
iTeos Therapeutics Inc. | ITOS | DiRocco Derek Director |
16,608 | $0 | 0 (Direct) |
View |
| 2021-06-17 Option Award |
2021-06-21 8:22 pm |
N/A 2031-06-17 |
iTeos Therapeutics Inc. | ITOS | Van Hauwermeiren Timothy Director |
16,608 | $0 | 0 (Direct) |
View |
| 2021-06-17 Option Award |
2021-06-21 8:21 pm |
N/A 2031-06-17 |
iTeos Therapeutics Inc. | ITOS | Ho Tony W Director |
4,560 | $0 | 4,560 (Direct) |
View |
| 2021-06-17 Option Award |
2021-06-21 8:18 pm |
N/A 2031-06-17 |
iTeos Therapeutics Inc. | ITOS | RODEN MATTHEW Director |
16,608 | $0 | 0 (Direct) |
View |
| 2021-06-17 Option Award |
2021-06-21 8:17 pm |
N/A 2031-06-17 |
iTeos Therapeutics Inc. | ITOS | Davis Aaron I. Director |
16,608 | $0 | 16,608 (Direct) |
View |
| 2021-06-17 Option Award |
2021-06-21 8:17 pm |
N/A 2031-06-17 |
iTeos Therapeutics Inc. | ITOS | RHOADS ANN D Director |
16,608 | $0 | 16,608 (Direct) |
View |
| 2021-06-17 Option Award |
2021-06-21 8:13 pm |
N/A 2031-06-17 |
iTeos Therapeutics Inc. | ITOS | Hallal David Director |
16,608 | $0 | 16,608 (Direct) |
View |
| 2021-06-08 Exercise |
2021-06-10 5:35 pm |
N/A 2030-05-01 |
iTeos Therapeutics Inc. | ITOS | McGrath Yvonne VP, Research and Development |
7,927 | $0 | 95,123 (Direct) |
View |
| 2021-06-08 Exercise |
2021-06-10 5:35 pm |
N/A N/A |
iTeos Therapeutics Inc. | ITOS | McGrath Yvonne VP, Research and Development |
7,927 | $4.23 | 95,123 (Direct) |
View |
| 2021-05-24 Exercise(A) |
2021-06-03 4:19 pm |
N/A 2030-05-01 |
iTeos Therapeutics Inc. | ITOS | McGrath Yvonne VP, Research and Development |
7,927 | $0 | 110,977 (Direct) |
View |
| 2021-05-24 Exercise(A) |
2021-06-03 4:19 pm |
N/A N/A |
iTeos Therapeutics Inc. | ITOS | McGrath Yvonne VP, Research and Development |
7,927 | $4.23 | 110,977 (Direct) |
View |
| 2021-06-01 Exercise |
2021-06-03 4:17 pm |
N/A 2030-05-01 |
iTeos Therapeutics Inc. | ITOS | McGrath Yvonne VP, Research and Development |
7,927 | $0 | 206,423 (Direct) |
View |
| 2021-06-01 Exercise |
2021-06-03 4:17 pm |
N/A N/A |
iTeos Therapeutics Inc. | ITOS | McGrath Yvonne VP, Research and Development |
7,927 | $4.23 | 206,423 (Direct) |
View |
| 2021-05-24 Exercise |
2021-05-26 4:09 pm |
N/A 2030-05-01 |
iTeos Therapeutics Inc. | ITOS | McGrath Yvonne VP, Research and Development |
7,927 | $0 | 110,977 (Direct) |
View |
| 2021-05-24 Exercise |
2021-05-26 4:09 pm |
N/A N/A |
iTeos Therapeutics Inc. | ITOS | McGrath Yvonne VP, Research and Development |
7,927 | $4.23 | 110,977 (Direct) |
View |
| 2021-05-17 Exercise |
2021-05-19 4:14 pm |
N/A 2030-05-01 |
iTeos Therapeutics Inc. | ITOS | McGrath Yvonne VP, Research and Development |
7,926 | $0 | 118,904 (Direct) |
View |
| 2021-05-17 Exercise |
2021-05-19 4:14 pm |
N/A N/A |
iTeos Therapeutics Inc. | ITOS | McGrath Yvonne VP, Research and Development |
7,926 | $4.23 | 118,904 (Direct) |
View |
| 2021-04-29 Option Award |
2021-05-03 7:09 pm |
N/A 2031-04-29 |
iTeos Therapeutics Inc. | ITOS | Iannone Robert Director |
33,217 | $0 | 0 (Direct) |
View |